AI is about to change healthcare. These 9 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Kao, you need to believe its shift toward higher value brands and overseas growth can offset slower demand and cost pressures in mature markets. The Curél Nordic launch supports the nearer term catalyst of expanding international cosmetics sales, but does not materially change the key risk that overseas growth could still lag expectations if competition and consumer spending remain challenging outside Japan.
The most relevant recent update here is Kao’s raised full year 2026 guidance, with net sales now forecast at ¥1,800.0 billion and net income at ¥135.0 billion. That upgrade reflects progress in improving profitability and scaling focus brands, so investors watching Curél’s European rollout may see it as one part of a broader push to lift margins and reduce reliance on the domestic Japanese market.
However, investors also need to be aware that overseas sales targets could be pressured if...
Read the full narrative on Kao (it's free!)
Kao's narrative projects ¥1,916.3 billion revenue and ¥157.9 billion earnings by 2029. This requires 3.8% yearly revenue growth and a ¥29.7 billion earnings increase from ¥128.2 billion today.
Uncover how Kao's forecasts yield a ¥3681 fair value, in line with its current price.
Three Simply Wall St Community fair value estimates for Kao cluster between ¥3,437.86 and ¥3,741.15, showing how much individual views can differ. Against this, the key risk that overseas expansion underdelivers on growth expectations could shape how you weigh those varied opinions and decide which scenarios for Kao’s performance feel most credible.
Explore 3 other fair value estimates on Kao - why the stock might be worth as much as ¥3741!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com